LIVIVO - Search results -

Search results

Result 1 - 10 of total 111

Search options

Article ; Online: Serum anti-Spike immunoglobulin G levels in random blood donors in Italy: High-titre convalescent plasma is easier than ever to procure.

Focosi, Daniele / Meschi, Silvia / Coen, Sabrina / Iorio, Maria Carla / Franchini, Massimo / Lanza, Maria / Maggi, Fabrizio

Vox sanguinis

2023 Volume 118, Issue 9, Page(s) 794–797

Abstract: Background and objectives: COVID-19 convalescent plasma (CCP) has retained potency and clinical efficacy against SARS-CoV-2 and is currently of utmost value for seronegative immunocompromised patients. Since most of the effect is due to the vaccine ... ...

Abstract	Background and objectives: COVID-19 convalescent plasma (CCP) has retained potency and clinical efficacy against SARS-CoV-2 and is currently of utmost value for seronegative immunocompromised patients. Since most of the effect is due to the vaccine boost of infection-elicited antibodies, there is a theoretical concern that the frequency of suitable donors is declining. Materials and methods: In this single-institution serosurvey, we screened 599 consecutive donors attending our area in two different seasons (300 in November 2022 and 299 in February 2023) using the Abbott Alinity® anti-Spike immunoglobulin G assay. Results: More than 80% of random donors qualify according to the FDA criteria for high-titre CCP (>4350 AU/mL), with a stable trend. Conclusion: Despite reduced anti-Spike vaccine boost deployment in the general population, we have shown here that high-titre CCP units are easier than ever to procure. This finding also has implications for the derivation of standard immunoglobulins, which are finally approaching the potency of hyperimmune serum and could soon represent an alternative to CCP.
MeSH term(s)	Humans ; Blood Donors ; COVID-19/therapy ; COVID-19 Serotherapy ; SARS-CoV-2 ; Cancer Vaccines ; Italy ; Immunoglobulin G ; Antibodies, Viral/therapeutic use ; Immunization, Passive ; Antibodies, Neutralizing
Chemical Substances	Cancer Vaccines ; Immunoglobulin G ; Antibodies, Viral ; Antibodies, Neutralizing
Language	English
Publishing date	2023-07-25
Publishing country	England
Document type	Journal Article
ZDB-ID	80313-3
ISSN	1423-0410 ; 0042-9007
ISSN (online)	1423-0410
ISSN	0042-9007
DOI	10.1111/vox.13498
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 74: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Effect of chemical and physical agents on monkeypox virus infectivity and downstream research applications.

Mariotti, Davide / Bettini, Aurora / Meschi, Silvia / Notari, Stefania / Francalancia, Massimo / Tartaglia, Eleonora / Lapa, Daniele / Specchiarello, Eliana / Girardi, Enrico / Matusali, Giulia / Maggi, Fabrizio

Virology

2024 Volume 592, Page(s) 109993

Abstract: The 2022 global spread of Monkeypox Virus (MPXV) underlined the need to investigate safe-handling procedures of clinical and research samples. Here we evaluated the efficiency in reducing MPXV infectious titer of Triton X-100 (0.1 and 0.2%), UV-C ... ...

Abstract	The 2022 global spread of Monkeypox Virus (MPXV) underlined the need to investigate safe-handling procedures of clinical and research samples. Here we evaluated the efficiency in reducing MPXV infectious titer of Triton X-100 (0.1 and 0.2%), UV-C irradiation (15 or 30 min), and heat (56 °C 30 min or 70 °C 5 min). The treatment of MPXV at 70 °C resulted in the strongest decrease of MPXV infectious titer (5.4 Log TCID50/mL), 56 °C and UV-C had a lighter impact (3.9 and 4.3Log), Triton X-100 was less efficient (1.8-2.5Log). Notably, SARS-CoV-2 was much more susceptible to Triton X-100 (4.0 Log decrease). UV-C had the highest impact on MPXV DNA detection by PCR (2.2-4.3 Ct value increase); protein detection by ELISA was dramatically impaired by heating. Overall, UV-C and heating were more effective in lowering MPXV infectious titer but their impact on nucleic acids or protein detection assays must be considered.
MeSH term(s)	Humans ; Monkeypox virus/genetics ; Mpox (monkeypox) ; Octoxynol ; SARS-CoV-2
Chemical Substances	Octoxynol (9002-93-1)
Language	English
Publishing date	2024-01-16
Publishing country	United States
Document type	Journal Article
ZDB-ID	200425-2
ISSN	1096-0341 ; 0042-6822
ISSN (online)	1096-0341
ISSN	0042-6822
DOI	10.1016/j.virol.2024.109993
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ud II Zs.172: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Occult HBV Infection in Patients Infected by HIV or HCV: Comparison between HBV-DNA and Two Assays for HBsAg.

Meschi, Silvia / Mizzoni, Klizia / Leoni, Bruno Daniele / Galli, Claudio / Garbuglia, Anna Rosa / Belladonna, Stefano / Girardi, Enrico / Maggi, Fabrizio / The Hbsagn Study Group

Viruses

2024 Volume 16, Issue 3

Abstract: We investigated the frequency and serological correlates of occult hepatitis B virus infection (OBI) and the potential impact of a highly sensitive assay for HBsAg in subjects infected by human immunodeficiency virus (HIV) or hepatitis C virus (HCV), who ...

Abstract	We investigated the frequency and serological correlates of occult hepatitis B virus infection (OBI) and the potential impact of a highly sensitive assay for HBsAg in subjects infected by human immunodeficiency virus (HIV) or hepatitis C virus (HCV), who are also at risk for hepatitis B virus (HBV) infection, often in an occult form. Samples from 499 patients with HIV, all HBsAg negative and anti-HBc positive, and 137 patients with HCV were tested for HBV-DNA, anti-HBc, anti-HBs, and HBsAg by a conventional and highly sensitive assay. HBV biomarkers were detected in 71.5% of HCV-RNA-positive, with a higher prevalence of cases positive only for anti-HBc in patients with HCV than in those with HIV. HBV-DNA was detectable in 0.6% of HIV-positive and 7.3% of HCV-RNA-positive patients. Among patients with HCV, four were positive for HBsAg and negative for HBV-DNA, bringing the rate of HBV-active infection in this group to 10.2%. Active HBV infection was not related to gender or specific patterns of HBV biomarkers but was higher in HCV patients coinfected by HIV compared to those infected only by HCV. Monitoring patients at high risk for HBV infection and reactivation may require testing for both HBV-DNA and HBsAg.
MeSH term(s)	Humans ; Hepatitis B virus/genetics ; Hepacivirus/genetics ; Hepatitis B Surface Antigens ; DNA, Viral ; HIV/genetics ; HIV Infections ; Hepatitis B/diagnosis ; Hepatitis B/epidemiology ; Hepatitis C/diagnosis ; Hepatitis C/epidemiology ; Hepatitis B, Chronic ; Hepatitis B Antibodies ; Prevalence ; Biomarkers ; RNA
Chemical Substances	Hepatitis B Surface Antigens ; DNA, Viral ; Hepatitis B Antibodies ; Biomarkers ; RNA (63231-63-0)
Language	English
Publishing date	2024-03-07
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2516098-9
ISSN	1999-4915 ; 1999-4915
ISSN (online)	1999-4915
ISSN	1999-4915
DOI	10.3390/v16030412
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Poor durability of the neutralizing response against XBB sublineages after a bivalent mRNA COVID-19 booster dose in persons with HIV.

Matusali, Giulia / Vergori, Alessandra / Cimini, Eleonora / Mariotti, Davide / Mazzotta, Valentina / Lepri, Alessandro Cozzi / Colavita, Francesca / Gagliardini, Roberta / Notari, Stefania / Meschi, Silvia / Fusto, Marisa / Tartaglia, Eleonora / Girardi, Enrico / Maggi, Fabrizio / Antinori, Andrea

Journal of medical virology

2024 Volume 96, Issue 4, Page(s) e29598

Abstract: We estimated the dynamics of the neutralizing response against XBB sublineages and T cell response in persons with HIV (PWH) with previous AIDS and/or CD4 < 200/ ... ...

Abstract	We estimated the dynamics of the neutralizing response against XBB sublineages and T cell response in persons with HIV (PWH) with previous AIDS and/or CD4 < 200/mm
MeSH term(s)	Humans ; COVID-19/prevention & control ; Immunization Programs ; RNA, Messenger ; Seasons ; mRNA Vaccines ; HIV Infections ; Antibodies, Neutralizing ; Antibodies, Viral
Chemical Substances	RNA, Messenger ; mRNA Vaccines ; Antibodies, Neutralizing ; Antibodies, Viral
Language	English
Publishing date	2024-04-16
Publishing country	United States
Document type	Journal Article
ZDB-ID	752392-0
ISSN	1096-9071 ; 0146-6615
ISSN (online)	1096-9071
ISSN	0146-6615
DOI	10.1002/jmv.29598
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1320: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: JN.1 neutralizing antibody titers after XBB.1.5 monovalent vaccine boost in healthcare workers and people with HIV.

Matusali, Giulia / Mazzotta, Valentina / Meschi, Silvia / Colavita, Francesca / Gagliardini, Roberta / Bettini, Aurora / Gruber, Cesare Ernesto Maria / Vergori, Alessandra / Gallì, Paola / Focosi, Daniele / Girardi, Enrico / Antinori, Andrea / Maggi, Fabrizio

Journal of medical virology

2024 Volume 96, Issue 5, Page(s) e29631

MeSH term(s)	Humans ; Health Personnel ; HIV Infections/immunology ; HIV Infections/prevention & control ; Antibodies, Neutralizing/blood ; Antibodies, Neutralizing/immunology ; COVID-19 Vaccines/immunology ; COVID-19 Vaccines/administration & dosage ; Adult ; Male ; Female ; COVID-19/prevention & control ; COVID-19/immunology ; Immunization, Secondary ; HIV Antibodies/blood ; HIV Antibodies/immunology ; Middle Aged ; SARS-CoV-2/immunology
Chemical Substances	Antibodies, Neutralizing ; COVID-19 Vaccines ; HIV Antibodies
Language	English
Publishing date	2024-04-29
Publishing country	United States
Document type	Letter ; Research Support, Non-U.S. Gov't
ZDB-ID	752392-0
ISSN	1096-9071 ; 0146-6615
ISSN (online)	1096-9071
ISSN	0146-6615
DOI	10.1002/jmv.29631
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1320: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: SARS-CoV-2 Breakthrough Infections According to the Immune Response Elicited after mRNA Third Dose Vaccination in COVID-19-Naïve Hospital Personnel.

Santoro, Annapaola / Capri, Andrea / Petrone, Daniele / Colavita, Francesca / Meschi, Silvia / Matusali, Giulia / Mizzoni, Klizia / Notari, Stefania / Agrati, Chiara / Goletti, Delia / Pezzotti, Patrizio / Puro, Vincenzo

Biomedicines

2023 Volume 11, Issue 5

Abstract: Background: Vaccine-induced SARS-CoV-2-anti-spike antibody (anti-S/RBD) titers are often used as a marker of immune protection and to anticipate the risk of breakthrough infections, although no clear cut-off is available. We describe the incidence of ... ...

Abstract	Background: Vaccine-induced SARS-CoV-2-anti-spike antibody (anti-S/RBD) titers are often used as a marker of immune protection and to anticipate the risk of breakthrough infections, although no clear cut-off is available. We describe the incidence of SARS-CoV-2 vaccine breakthrough infections in COVID-19-free personnel of our hospital, according to B- and T-cell immune response elicited one month after mRNA third dose vaccination. Methods: The study included 487 individuals for whom data on anti-S/RBD were available. Neutralizing antibody titers (nAbsT) against the ancestral Whuan SARS-CoV-2, and the BA.1 Omicron variant, and SARS-CoV-2 T-cell specific response were measured in subsets of 197 (40.5%), 159 (32.6%), and 127 (26.1%) individuals, respectively. Results: On a total of 92,063 days of observation, 204 participants (42%) had SARS-CoV-2 infection. No significant differences in the probability of SARS-CoV-2 infection for different levels of anti-S/RBD, nAbsT, Omicron nAbsT, or SARS-CoV-2 T cell specific response, and no protective thresholds for infection were found. Conclusions: Routine testing for vaccine-induced humoral immune response to SARS-CoV-2 is not recommended if measured as parameters of 'protective immunity' from SARS-CoV-2 after vaccination. Whether these findings apply to new Omicron-specific bivalent vaccines is going to be evaluated.
Language	English
Publishing date	2023-04-23
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2720867-9
ISSN	2227-9059
ISSN	2227-9059
DOI	10.3390/biomedicines11051247
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Torquetenovirus Loads in Peripheral Blood Predict Both the Humoral and Cell-Mediated Responses to SARS-CoV-2 Elicited by the mRNA Vaccine in Liver Transplant Recipients.

Minosse, Claudia / Matusali, Giulia / Meschi, Silvia / Grassi, Germana / Francalancia, Massimo / D'Offizi, Gianpiero / Spezia, Pietro Giorgio / Garbuglia, Anna Rosa / Montalbano, Marzia / Focosi, Daniele / Girardi, Enrico / Vaia, Francesco / Ettorre, Giuseppe Maria / Maggi, Fabrizio

Vaccines

2023 Volume 11, Issue 11

Abstract: Three years into the COVID-19 pandemic, mass vaccination campaigns have largely controlled the disease burden but have not prevented virus circulation. Unfortunately, many immunocompromised patients have failed to mount protective immune responses after ... ...

Abstract	Three years into the COVID-19 pandemic, mass vaccination campaigns have largely controlled the disease burden but have not prevented virus circulation. Unfortunately, many immunocompromised patients have failed to mount protective immune responses after repeated vaccinations, and liver transplant recipients are no exception. Across different solid organ transplant populations, the plasma levels of Torquetenovirus (TTV), an orphan and ubiquitous human virus under control of the immune system, have been shown to predict the antibody response after COVID-19 vaccinations. We show here a single-institution experience with TTV viremia in 134 liver transplant recipients at their first or third dose. We found that TTV viremia before the first and third vaccine doses predicts serum anti-SARS-CoV-2 Spike receptor-binding domain (RBD) IgG levels measured 2-4 weeks after the second or third dose. Pre-vaccine TTV loads were also associated with peripheral blood anti-SARS-CoV-2 cell-mediated immunity but not with serum SARS-CoV-2 neutralizing antibody titers.
Language	English
Publishing date	2023-10-28
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2703319-3
ISSN	2076-393X
ISSN	2076-393X
DOI	10.3390/vaccines11111656
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: A microRNA Arising from the Negative Strand of SARS-CoV-2 Genome Targets FOS to Reduce AP-1 Activity.

Greco, Francesco / Lorefice, Elisa / Carissimi, Claudia / Laudadio, Ilaria / Ciccosanti, Fabiola / Di Rienzo, Martina / Colavita, Francesca / Meschi, Silvia / Maggi, Fabrizio / Fimia, Gian Maria / Fulci, Valerio

Non-coding RNA

2023 Volume 9, Issue 3

Abstract: Virus-encoded microRNAs were first reported in the Epstein-Barr virus in 2004. Subsequently, a few hundred viral miRNAs have been identified, mainly in DNA viruses belonging to ... ...

Abstract	Virus-encoded microRNAs were first reported in the Epstein-Barr virus in 2004. Subsequently, a few hundred viral miRNAs have been identified, mainly in DNA viruses belonging to the
Language	English
Publishing date	2023-05-23
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2813993-8
ISSN	2311-553X ; 2311-553X
ISSN (online)	2311-553X
ISSN	2311-553X
DOI	10.3390/ncrna9030033
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Pre-exposure prophylaxis with tixagevimab/cilgavimab in patients with chronic lymphocytic leukaemia treated with targeted agents.

Mauro, Francesca R / Visentin, Andrea / Giannarelli, Diana / Molinari, Maria C / Proietti, Giulia / Petrella, Marco / Angotzi, Francesco / Pepe, Sara / Trentin, Livio / Baroncelli, Silvia / Giombini, Emanuela / Meschi, Silvia / Maggi, Fabrizio / Focosi, Daniele

British journal of haematology

2023 Volume 201, Issue 3, Page(s) 564–567

MeSH term(s)	Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Pre-Exposure Prophylaxis ; Antineoplastic Agents/therapeutic use
Chemical Substances	tixagevimab ; cilgavimab (1KUR4BN70F) ; Antineoplastic Agents
Language	English
Publishing date	2023-02-22
Publishing country	England
Document type	Letter
ZDB-ID	80077-6
ISSN	1365-2141 ; 0007-1048
ISSN (online)	1365-2141
ISSN	0007-1048
DOI	10.1111/bjh.18701
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.182: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Profiling the acute phase antibody response against mpox virus in patients infected during the 2022 outbreak.

Colavita, Francesca / Matusali, Giulia / Mazzotta, Valentina / Bettini, Aurora / Lapa, Daniele / Meschi, Silvia / Francalancia, Massimo / Pinnetti, Carmela / Bordi, Licia / Mizzoni, Klizia / Coen, Sabrina / Girardi, Enrico / Vaia, Francesco / Nicastri, Emanuele / Antinori, Andrea / Maggi, Fabrizio

Journal of medical virology

2023 Volume 95, Issue 6, Page(s) e28851

Abstract: Information on the immune response during the mpox virus (MPXV) infection is still scarce or limited to past studies when cross-reactive immunity from smallpox vaccination was predominant. Here, we describe the short-term kinetics of the antibody ... ...

Abstract	Information on the immune response during the mpox virus (MPXV) infection is still scarce or limited to past studies when cross-reactive immunity from smallpox vaccination was predominant. Here, we describe the short-term kinetics of the antibody response in patients with acute MPXV infection during the 2022 multicountry outbreak. A total of 64 samples from 18 MPXV-positive patients were longitudinally collected from the day of symptom onset (DSO) up to 20 days after and tested for anti-MPXV immunoglobulin G (IgG), IgM, IgA, and neutralizing antibodies (nAb) using the whole-live virus isolated in May 2022. IgG, IgM, and IgA were detected as early as 4 DSO (median time of seroconversion 7.5 DSO for IgG, 8 DSO for IgM and IgA). Anti-MPXV nAb were detectable in samples collected as early as 1 week after symptoms, with stable levels up to 20 DSO. After 2 weeks, IgG and nAb reached high titers. No significant differences were observed regardless of status of smallpox vaccination, human immunodeficiency virus positivity, or disease severity. Significant lower levels of IgM and IgG were observed in the patients treated with antivirals. These results contribute to extending the knowledge of the MPXV infection and the antibody response in a population with no historic smallpox vaccination.
MeSH term(s)	Humans ; Monkeypox virus ; Immunoglobulin G ; Immunoglobulin M ; Smallpox ; Antibody Formation ; Antibodies, Viral ; Antibodies, Neutralizing ; Immunoglobulin A ; Disease Outbreaks
Chemical Substances	Immunoglobulin G ; Immunoglobulin M ; Antibodies, Viral ; Antibodies, Neutralizing ; Immunoglobulin A
Language	English
Publishing date	2023-06-08
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	752392-0
ISSN	1096-9071 ; 0146-6615
ISSN (online)	1096-9071
ISSN	0146-6615
DOI	10.1002/jmv.28851
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1320: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito